Literature DB >> 21246351

Cytochrome P450 3A activity in mothers and their neonates as determined by plasma 4β-hydroxycholesterol.

Hanna Nylén1, Sofia Sergel, Lisa Forsberg, Synnöve Lindemalm, Leif Bertilsson, Katarina Wide, Ulf Diczfalusy.   

Abstract

PURPOSE: The purpose of this study was to determine the 4β-hydroxycholesterol to cholesterol ratio in mothers and neonates at the time of birth and 4 months post-partum.
METHOD: 21 mothers and 22 neonates were recruited at the delivery ward at Karolinska University Hospital, Huddinge, Sweden. Blood samples taken from mothers and neonates at birth and 4 months post-partum were analysed for 4β-hydroxycholesterol and cholesterol.
RESULTS: The median plasma concentration of 4β-hydroxycholesterol was higher in mothers at delivery (50 ng/mL) compared to healthy non-pregnant women (29 ng/mL). The pregnant women had a higher median cholesterol concentration (6.2 mmol/L) compared to healthy non-pregnant women (4.6 mmol/L) but this could only partly explain the increased 4β-hydroxycholesterol. The major cause is an increased CYP3A activity during pregnancy. The median 4β-hydroxycholesterol/cholesterol ratio·10(4) was elevated in mothers at time of birth compared to non-pregnant women (0.19 and 0.15, respectively) but decreased to 0.15 4 months post-partum. Neonates had a median 4β-hydroxycholesterol/cholesterol ratio·10(4) (0.19) comparable to adults already at birth, but lower 4β-hydroxycholesterol (12 ng/mL) and cholesterol (1.8 mmol/L) concentrations.
CONCLUSION: Pregnancy leads to increased CYP3A enzyme activity as determined by the 4β-hydroxycholesterol/cholesterol ratio. Neonates have low 4β-hydroxycholesterol and cholesterol concentrations but similar total CYP3A activity as adults already at birth.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21246351     DOI: 10.1007/s00228-010-0984-1

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  40 in total

Review 1.  The erythromycin breath test for the prediction of drug clearance.

Authors:  L P Rivory; K A Slaviero; J M Hoskins; S J Clarke
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 2.  Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes.

Authors:  D S Streetman; J S Bertino; A N Nafziger
Journal:  Pharmacogenetics       Date:  2000-04

3.  Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians.

Authors:  E Gebeyehu; E Engidawork; A Bijnsdorp; A Aminy; U Diczfalusy; E Aklillu
Journal:  Pharmacogenomics J       Date:  2010-03-16       Impact factor: 3.550

4.  CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population.

Authors:  Rajaa A Mirghani; Jane Sayi; Eleni Aklillu; Annika Allqvist; Mary Jande; Agneta Wennerholm; Jaran Eriksen; Virginie M M Herben; Barry C Jones; Lars L Gustafsson; Leif Bertilsson
Journal:  Pharmacogenet Genomics       Date:  2006-09       Impact factor: 2.089

5.  Ontogeny of dextromethorphan O- and N-demethylation in the first year of life.

Authors:  M J Blake; A Gaedigk; R E Pearce; L R Bomgaars; M L Christensen; C Stowe; L P James; J T Wilson; G L Kearns; J S Leeder
Journal:  Clin Pharmacol Ther       Date:  2007-02-14       Impact factor: 6.875

6.  Metabolism of 4 beta -hydroxycholesterol in humans.

Authors:  Karl Bodin; Ulla Andersson; Eva Rystedt; Ewa Ellis; Maria Norlin; Irina Pikuleva; Gösta Eggertsen; Ingemar Björkhem; Ulf Diczfalusy
Journal:  J Biol Chem       Date:  2002-06-20       Impact factor: 5.157

7.  Umbilical glutathione levels are higher after vaginal birth than after cesarean section.

Authors:  Maarten T M Raijmakers; Eva Maria Roes; Eric A P Steegers; Bas van der Wildt; Wilbert H M Peters
Journal:  J Perinat Med       Date:  2003       Impact factor: 1.901

Review 8.  Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals.

Authors:  M M Galteau; F Shamsa
Journal:  Eur J Clin Pharmacol       Date:  2003-11-06       Impact factor: 2.953

9.  The rhesus monkey as a model for studies of pregnancy induced changes in metoprolol metabolism.

Authors:  S Högstedt; B S Lindberg; C G Regårdh; U Moström; A Rane
Journal:  Pharmacol Toxicol       Date:  1990-01

10.  Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study.

Authors:  M F Hebert; T R Easterling; B Kirby; D B Carr; M L Buchanan; T Rutherford; K E Thummel; D P Fishbein; J D Unadkat
Journal:  Clin Pharmacol Ther       Date:  2008-02-20       Impact factor: 6.903

View more
  5 in total

1.  A Physiologically Based Pharmacokinetic Model for Pregnant Women to Predict the Pharmacokinetics of Drugs Metabolized Via Several Enzymatic Pathways.

Authors:  André Dallmann; Ibrahim Ince; Katrin Coboeken; Thomas Eissing; Georg Hempel
Journal:  Clin Pharmacokinet       Date:  2018-06       Impact factor: 6.447

Review 2.  A Physiology-Based Pharmacokinetic Framework to Support Drug Development and Dose Precision During Therapeutic Hypothermia in Neonates.

Authors:  Anne Smits; Pieter Annaert; Steven Van Cruchten; Karel Allegaert
Journal:  Front Pharmacol       Date:  2020-05-13       Impact factor: 5.810

3.  Sensitive UHPLC-MS/MS quantification method for 4β- and 4α-hydroxycholesterol in plasma for accurate CYP3A phenotyping.

Authors:  Yosuke Suzuki; Ayako Oda; Jun Negami; Daiki Toyama; Ryota Tanaka; Hiroyuki Ono; Tadasuke Ando; Toshitaka Shin; Hiromitsu Mimata; Hiroki Itoh; Keiko Ohno
Journal:  J Lipid Res       Date:  2022-02-16       Impact factor: 5.922

4.  Physiologically Based Pharmacokinetic Modeling in Pregnant Women Suggests Minor Decrease in Maternal Exposure to Olanzapine.

Authors:  Liang Zheng; Hongyi Yang; André Dallmann; Xuehua Jiang; Ling Wang; Wei Hu
Journal:  Front Pharmacol       Date:  2022-01-19       Impact factor: 5.810

5.  Pregnane X Receptor‒4β-Hydroxycholesterol Axis in the Regulation of Overweight- and Obesity-Induced Hypertension.

Authors:  Roosa Rahunen; Outi Kummu; Vesa Koivukangas; Heidi Hautajärvi; Jukka Hakkola; Jaana Rysä; Janne Hukkanen
Journal:  J Am Heart Assoc       Date:  2022-03-01       Impact factor: 6.106

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.